Domestic second HPV vaccine accepted and expected to be available within the next year or two

Pharmaceutical Network Industry Dynamic: Following the launch of the second-priceD HPV vaccine by Wantai Bio, the development of the second HPV vaccine in China has also achieved a breakthroughOn June 16, Watson Bio announced that the company's holding subsidiary Shanghai Zerun independently developed the "recombinant hpvoma virus double price (16/18) vaccine (yeast)" has submitted a new drug production application, and on June 15 by the State Drug AdministrationThe variety is expected to be available within the next year or twoit is understood that shanghai Zerun developed a divalent HPV vaccine for the prevention of HPV16 and 18 virus infection caused by cervical cancer, products for 9- to 30-year-old women who are not infected with 16 and 18 type of human papillomavirus (HPV)After the age-appropriate population is vaccinated against the vaccine, it can stimulate the body to produce immunity against HPV16 and 18 viruses, can prevent pre-cervical cancer lesions caused by the above-mentioned viral infection, and thus prevent cervical cancerfrom the research and development process of the vaccine, as early as June 1, 2011, the vaccine obtained the "Drug Clinical Trial Approval";at the end of April this year, the product was reported for clinical trials, which will be industrialized by Yuxi Zerun, a wholly owned subsidiary of Shanghai ZerunIn accordance with the provisions of the Vaccine Administration Law and other relevant laws and regulations, Yuxi Zerun submitted to the State Drug Administration an application for the production of new drugs for the vaccine and was acceptedAccording to the regulations, there are also procedures such as technical review, drug registration verification, drug registration inspection, etcon the evening of June 15, Watson Bio announced that the Shanghai Zerun divalent HPV vaccine completed Phase III clinical study in April 2020 and obtained the Clinical Trial Report, and on June 15, 2020 received the "Receiving Notice" issued by the State Drug Administration, indicating that the vaccine has entered the registration and approval stage of drug productionCurrently, the global market edified HPV vaccine, Mercado's quadrrate HPV vaccine and nine-price HPV vaccine, as well as China's Wantai Bohai divalent HPV vaccineGlobal sales of the HPV vaccine in 2019 totalled about $3.8 billion, according to the annual reports of GSK and MercadoWith the watson bio-divalent HPV vaccine approved, the subsequent success of the market, the industry believes that with its cost-effective instead of imports will make a significant contribution to the health of women in China, will also form a strong support for the company's performanceResearch data show that the domestic market HPV vaccine coverage of the age group for 9 to 45 years old women, assuming that the double price is 320 yuan / dose, and assume that 9 to 15 years old using 2 doses of vaccination procedures, four prices at 800 yuan / dose, nine prices at 1300 yuan / doseIf the total stock market size exceeds 30 billion yuan at 10% penetration rate, if the penetration rate of 9 to 26 years of age is assumed to be 20%, 27 to 45 years old is 10%, then the space or as much as 120 billion yuan, the market potential is considerable data show that Watson Bio is a professional professional human vaccine and other biotechnology drugs set research and development, production and sales of high-tech biopharmaceutical enterprises With its heavy-duty vaccine variety 13-valent pneumonia combined with vaccines and HPV vaccine and other products, the company is expected to usher in this year's performance inflection point.